Novel Hepatitis C Drugs in Current Trials
- 31 August 2008
- journal article
- review article
- Published by Elsevier in Clinics in Liver Disease
- Vol. 12 (3) , 529-555
- https://doi.org/10.1016/j.cld.2008.03.001
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis CHepatology, 2007
- Claudin-1 is a hepatitis C virus co-receptor required for a late step in entryNature, 2007
- Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2′- C -Methylcytidine, the Active Component of ValopicitabineAntimicrobial Agents and Chemotherapy, 2006
- 750 Preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical developmentJournal of Hepatology, 2006
- 751 The safety and efficacy of viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 resultsJournal of Hepatology, 2006
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJournal of Hepatology, 2005
- Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virusNature, 2005
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005
- 626 Pharmacokinetics and pharmacodynamics of valopicitabine (NM283), a new nucleoside HCV polymerase inhibitor: Results from a phase I/II dose-escalation trial in patients with HCV-1 infectionJournal of Hepatology, 2005
- The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, AmantadineFEBS Letters, 2002